Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 5/20 | 0.63 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.63 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.63 |
| ▸ | PIK3C2G | O75747 | 6/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16490454 | 0.93 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL31323380 | 0.90 | PIK3C2G (0.75) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL14851656 | 0.90 | PIK3C2G (0.75) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL16490596 | 0.88 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL16490450 | 0.85 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL16490346 | 0.85 | PIK3CD (0.80) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL16490449 | 0.85 | PI4KB (0.65) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL16490386 | 0.84 | PIK3CG (0.66) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL16490447 | 0.83 | PIK3CG (0.65) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA | |
| SCHEMBL16490358 | 0.83 | PIK3CG (0.69) | PIK3CGPIK3CDPIK3C3PIK3C2GPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170924-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2018-06-21 | — | — | US | disclosed |
| US-9926309-B2 | Pi-kinase inhibitors with anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160194314-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
| US-9309236-B2 | PI-kinase inhibitors with broad spectrum anti-infective activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150051193-A1 | PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051193-A1 | PI-kinase Inhibitors with Broad Spectrum Anti-Infective Activity | PIP4K2A, PIP5K1A, PIP4K2C | PIK3CG 22/4885PIK3CD 20/4885PIK3C3 29/4885 |
| US-20180170924-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | PIP4K2A, PIP5K1A, PIP4K2C | PIK3CG 21/4885PIK3CD 20/4885PIK3C3 27/4885 |
| US-20160194314-A1 | PI-KINASE INHIBITORS WITH ANTI-INFECTIVE ACTIVITY | PIP4K2A, PIP5K1A, PIP4K2C | PIK3CG 21/4885PIK3CD 20/4885PIK3C3 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.